Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 80,707	$ 35,041
Prepaid expenses and other	1,071	1,168
Total current assets	81,898	37,171
Equipment, net	3,163	2,882
Deposits and other	1,375	1,613
Total assets	86,436	41,666
Current liabilities:
Accrued compensation and related benefits	1,066	773
Accrued clinical trial related costs	750	1,160
Accrued expenses and other	1,592	723
Total current liabilities	16,872	12,837
Other long-term liabilities	48	220
Stockholders’ equity:
Preferred stock, at stated value; 10,000,000 shares authorized, and no shares issued and outstanding at June 30, 2020 and December 31, 2019	0	0
Common stock, $0.001 par value; 300,000,000 shares authorized, and 197,008,562 and 159,791,585 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively	197	160
Additional paid-in capital	515,621	440,735
Accumulated deficit	(451,640)	(417,624)
Total stockholders’ equity	64,178	23,271
Total liabilities and stockholders’ equity	86,436	41,666
Consolidated entity excluding, related party
Current assets:
Accounts receivable	24	17
Current liabilities:
Accounts payable	12,331	9,048
Healios
Current assets:
Accounts receivable	96	945
Current liabilities:
Accounts payable	1,068	1,068
Deferred revenue - Healios	65	65
Advance from Healios	$ 5,338	$ 5,338